MedPath

Sequential Administration of egg development medications to the women having polycystic ovarian disease who were not responding to clomiphene citrate and treated with 3 months of oral contraceptive pill for 3 months to create hormonal balance .

Not Applicable
Conditions
Health Condition 1: N970- Female infertility associated withanovulation
Registration Number
CTRI/2022/10/046305
Lead Sponsor
JIPMER Intramural Research Fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Clomiphene citrate resistant polycystic ovarian syndrome women who had pretreatment with OCPs

2 BMI not more than 28

3 Normal Semen Analysis, according to 2020 WHO criteria

4 Bilateral patent tubes

Exclusion Criteria

1 Associated with Uterine or adnexal pathology as a cause for infertility .

2 History of pelvic surgery or pelvic inflammatory disease

3 Presence of Ovarian cysts

4 Thyroid or prolactin dysfunction

5 Any sensitivity to the drugs used.

6 Any history suggestive of high risk of thrombosis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To Compare the efficacy Sequential Clomiphene Citrate /Letrozole with human Menopausal Gonadotropin for ovulation induction in CC resistant women with PCOS pretreated with OCPs containing Ethinyl estradiol 30ug and Drosperinone 3mg.Timepoint: outcome assessed at around day 16- day 19 in each cycle for 3 months to look for ovulation after follicular rupture i.e, in the 3rd week of each cycle
Secondary Outcome Measures
NameTimeMethod
To compare the pregnancy rate and live birth rate between both the gruopsTimepoint: 3 - 6 months
© Copyright 2025. All Rights Reserved by MedPath